The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Clinical activity of abemaciclib in patients with R/R MCL
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, discusses the clinical activity of abemaciclib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). In this study, abemaciclib showed clinical activity. Single agent abemaciclib demonstrated a disease control rate (DCR) based on the Response Criteria for Non-Hodgkin Lymphoma (NHL) of 71.4%. At a median follow-up time of 13.8 months, median duration of response (DoR) was 12.39 months and median overall survival (OS) was 16.03 months. The objective response rate (ORR) of abemaciclib was 35.7%, which is comparable to bortezomib and lenalidomide – both approved agents for MCL treatment. Dr Hess also comments on the safety and tolerability data observed in the study. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
